Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 4 3Phase 1 3Phase NA 2Phase EARLY_PHASE1 2Phase 3 1

Status

Withdrawn 2Recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × posaconazole × Clear all
NCT07155226 2026-05-19

MOMENTUM

AstraZeneca

Phase 1/2 Recruiting
84 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

BeOne Medicines

Phase 1/2 Recruiting
260 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03036046 2018-02-15

SAFEGUARDFP

F2G Biotech GmbH

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡